Table I.

Demographics of patients with CVID who received Evusheld

Characteristic	Value
N	45
Age (y), median (range)	62.0 (15.5-85.8)
Sex (male), no. (%)	17 (37%)
Vaccinated, no. (%)	41 (91%)
Pfizer vaccine	12 (29%)
Moderna vaccine	23 (56%)
Combination mRNA vaccines	4 (10%)
Janssen vaccine	1 (2%)
Janssen mRNA booster	1 (2%)
Received 4 doses of mRNA vaccine, no. (%)	11 (28%)
Pre-Evusheld COVID-19 infection, no. (%)	8 (18%)
Time between COVID-19 infection and Evusheld (d), median (range)	307 (45-463)
Received 600-mg total dose, no. (%)	41 (91%)
Follow-up after Evusheld (d)	19 (0-81)
Adverse events after Evusheld, no. (%)	6 (13%)
Cardiac risk factors, no. (%)
Hypertension	19 (42%)
Daily aspirin therapy	15 (33%)
Hyperlipidemia	13 (29%)
Diabetes mellitus	6 (13%)
History of myocardial infarction	1 (2%)